On 1 September 2025, STADA announced that international private equity investment firm, CapVest Partners LLP, has signed a definitive agreement to acquire the majority stake in the company. The transaction is expected to close in H1 2026, subject to regulatory approvals and other closing conditions.
The majority stake in STADA is currently held by Bain Capital and Cinven, which will each retain a minority stake after the CapVest acquisition.
STADA has a number of strategic biosimilars partnerships, including with Bio-Thera in relation to tocilizumab and golimumab biosimilars in the EU, UK and Switzerland, and with Alvotech in relation to Uzpruvo®, the first European approved and launched biosimilar to J&J/Janssen’s Stelara® (ustekinumab) (January/July 2024), biosimilar denosumab (AVT03, MAA accepted by EMA in October 2024) and Hukyndra® (citrate-free 100mg/ml biosimilar adalimumab) launched in Europe in 2022.
In June 2025, STADA’s Afiveg®, biosimilar to Regeneron/Bayer’s Eylea® (aflibercept), received a positive CHMP opinion for treatment of nAMD and visual impairment due to macular oedema secondary to retinal vein occlusion/diabetic macular oedema (DME)/myopic choroidal neovascularisation. STADA/Xbrane’s Ximluci®, biosimilar to Genentech’s Lucentis® (ranibizumab), was launched in Europe in April 2023.